Oxygenta Pharmaceutical Ltd

Oxygenta Pharmaceutical Ltd has announced that its Board of Directors will convene on November 10, 2026. The meeting agenda includes the consideration and approval of the un-audited financial results for the quarter and half-year ended September 30, 2026, along with the Limited Review Report for the same period. The meeting will be held at the company's corporate office.

Oxygenta Pharmaceutical Ltd has announced the final allotment of a plot of land measuring 36,421 Sq. Mtrs. at UDL-Aroor, Sangareddy District, Telangana, from Telangana Industrial Infrastructure Corporation Limited (TGIIC). The total consideration for this land acquisition is ₹6,75,24,534/- (Rupees Six Crore Seventy-Five Lakh Twenty-Four Thousand Five Hundred and Thirty-Four Only). This strategic acquisition is aimed at supporting the company's business operations, facilitating future expansion, and establishing additional infrastructure to meet long-term strategic requirements. The company expects this move to enhance its operational capabilities and provide adequate infrastructure for anticipated business growth. The transaction's value exceeds the materiality threshold, necessitating this disclosure.

Oxygenta Pharmaceutical Ltd has announced the closure of its trading window for all designated persons, their immediate relatives, and connected persons. This closure is effective from October 1, 2026, and will remain in effect until 48 hours after the declaration of the financial results for the quarter and half-year ending September 30, 2026. The company will convene a board meeting to approve these financial results. This measure is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct to prevent insider trading.

Oxygenta Pharmaceutical Ltd has submitted its 33rd Annual Report for the Financial Year 2025-26, in compliance with Regulation 34 of SEBI (LODR) Regulations, 2015. The report was dispatched to shareholders on July 30, 2026. The company has also scheduled its 33rd Annual General Meeting (AGM) for August 21, 2026, at 10:30 AM, to be conducted via Video Conference/Other Audio-Visual Means. The AGM agenda includes the adoption of audited financial statements for FY26 and the re-appointment of a director retiring by rotation. A web-link to the Annual Report is available on the company's website for members who have not registered their email addresses.

Oxygenta Pharmaceutical Ltd has issued a notice for its 33rd Annual General Meeting (AGM) for the Financial Year 2025-26. The AGM is scheduled to be held on Friday, August 21, 2026, at 10:30 AM via Video Conference (VC) or Other Audio-Visual Means. The annual report, along with the notice, was dispatched on July 30, 2026. For members who have not registered their email addresses, a letter with the web-link to the Annual Report is available on the company's website. The filing complies with Regulation 34 of SEBI (LODR) Regulations, 2015.

Oxygenta Pharmaceutical Ltd announced its un-audited financial results for the quarter ended June 30, 2026. The Board of Directors also approved the appointment of M/s. PCR & Associates as Cost Auditors for FY 2026-27 and scheduled the Annual General Meeting for August 21, 2026. The POSH Committee of the Board was re-constituted.

Oxygenta Pharmaceutical Ltd announced the appointment of M/s. PCR & Associates, Cost Accountants, as the company's Cost Auditors for the Financial Year 2026-27. This decision was approved by the Board of Directors during their meeting held on July 27, 2026. The board also approved the un-audited financial results for the quarter ended June 30, 2026, and the notice for the Annual General Meeting for FY 2025-26, scheduled for August 21, 2026. Additionally, the POSH Committee of the Board was re-constituted.

Oxygenta Pharmaceutical Ltd announced its un-audited financial results for the quarter ended June 30, 2026. The Board of Directors also approved the appointment of M/s. PCR & Associates as Cost Auditors for FY 2026-27 and scheduled the Annual General Meeting for August 21, 2026. The POSH Committee of the Board was re-constituted.

Oxygenta Pharmaceutical Ltd has announced the postponement of its Board Meeting, originally scheduled for July 25, 2026. The meeting has been rescheduled to July 27, 2026. The purpose of the meeting is to consider and approve the unaudited financial results for the quarter ended June 30, 2026, along with the Limited Review Report for the same period. Any other business, with the permission of the Chair, will also be discussed. The meeting will be held at the company's corporate office.

Oxygenta Pharmaceutical Ltd has announced that its Board of Directors will convene on Saturday, July 25, 2026. The primary agenda items include the consideration and approval of the un-audited financial results for the quarter ended June 30, 2026, along with the associated Limited Review Report. The meeting will also address any other business as permitted by the Chair. This notification is in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.